FirstEnergy Corp. vs Neurocrine Biosciences Inc — how do they compare? FirstEnergy Corp. trades at $49.21 (market cap $28.13B), while Neurocrine Biosciences Inc trades at $170.91 (market cap $17.30B). The key difference: FirstEnergy Corp. is the larger of the two by market cap, and FirstEnergy Corp. pays a 3.82% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| FE | NBIX | |
|---|---|---|
Market Cap | $28.13B | $17.30B |
Sector | Utilities | Health |
52-Week High | $51.91 | $180.55 |
52-Week Low | $40.30 | $123.10 |
Enterprise Value | $56.14B | $16.39B |
Dividend Yield | 3.82% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $171.81, down slightly by 0.1% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $1.94 versus $1.22 expected, and robust profitability metrics like a 98.17% gross margin. Recent news highlights pipeline advancements and a Zacks upgrade to Strong Buy, reflecting positive sentiment.
Outlook remains positive with a consensus price target of $195.75, implying 14% upside. Key opportunities include sustained revenue growth and pipeline progress, while risks involve execution on recent acquisitions and competitive pressures. The stock is well-positioned for momentum but requires monitoring of Q2 2026 results due July 30.
Trailing returns across standard periods
Latest headlines on both assets
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →